Niemann-Pick C1-like protein (NPC1L1) mediates the absorption of dietary cholesterol in the proximal region of the intestine, a process that is blocked by cholesterol absorption inhibitors (CAIs), including ezetimibe (EZE). Using a proteomic approach, we demonstrate that NPC1L1 is the protein to which EZE and its analogs bind. Next, we determined the site of interaction of EZE analogs with NPC1L1 by exploiting the different binding affinities of mouse and dog NPC1L1 for the radioligand analog of EZE, [ 3 H]AS. Chimeric and mutational studies indicate that high-affinity binding of 
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hole-body cholesterol homeostasis is maintained through three major pathways: de novo synthesis, intestinal absorption, and biliary excretion. Absorption of dietary and biliary cholesterol occurs in the proximal jejunum of the small intestine (1) , and this process is blocked by ezetimibe (EZE), a drug used for the treatment of hypercholesterolemia. EZE, a potent cholesterol and phytosterol uptake inhibitor, effectively lowers circulating plasma cholesterol in humans by 15-20% (2) , and its coadministration with 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase inhibitors (statins), inhibitors of cholesterol synthesis, leads to further reductions in cholesterol plasma levels (3) .
By searching expressed sequence tag databases for the presence of a sterol-sensing domain (SSD), a plasma membrane secretion signal, and enriched expression in intestinal enterocytes, the Niemann-Pick C1-Like 1 (NPC1L1) protein was identified in 2004 as a potential candidate gene for the EZE-sensitive pathway of cholesterol absorption (4) . Mice deficient in NPC1L1 were found to have Ϸ70% reduction in sterol absorption, with the residual component being insensitive to EZE (4) , suggesting that NPC1L1 is a critical component of cholesterol uptake in enterocytes (4) . The use of enterocyte brush border membranes (BBMs) from several species, including NPC1L1 KO mice (5) , or membranes derived from cells expressing recombinant NPC1L1, has provided strong evidence for NPC1L1 being the target to which EZE binds (5) .
More recently, in vitro studies have demonstrated EZE-sensitive cholesterol transport into McArdles RH7777 hepatoma (6), CaCo-2 (7), and MDCKII cells (8) overexpressing NPC1L1. However, although EZE-sensitive cholesterol transport correlates well with the amount of NPC1L1 expression (7, 8) , it is not possible to determine whether NPC1L1 functions alone or as part of a multiprotein complex [SR-B1 (9-15), CD36 (14), CD13 (9) , caveolin-1/annexin-2 (16) ], facilitating the transfer of cholesterol from outside the cell to internal cholesterol pools (9, 15) . Furthermore, it has been speculated that EZE may inhibit cholesterol transfer by binding to some of these other targets, in addition to its inhibition of NPC1L1 (9) .
In the present study, we attempted to determine whether EZE binds to NPC1L1 directly by purifying an EZE-NPC1L1 complex and analyzing its constituents by mass spectrometry. Quantitative analysis unambiguously demonstrated that NPC1L1 is the only protein to account for EZE binding. Subsequently, using a chimera/ mutagenesis approach that takes advantage of the large difference in affinities between dog and mouse NPC1L1 for EZE-like compounds, we identified two residues in a large extracellular loop of NPC1L1 that are mostly responsible for the large difference in affinity between the two species, and that reside adjacent to a hotspot of human polymorphisms associated with reduced cholesterol absorption (17) . Based on the assumption that region(s) associated with cholesterol binding to NPC1L1 and its close homologue NPC1 are similar, we propose a model for the action of EZE on NPC1L1-mediated cholesterol absorption. In this model, cholesterol binds to an extracellular binding site on NPC1L1 and is transported across the membrane through an undisclosed mechanism. EZE binding to a distinct extracellular site in NPC1L1 prevents certain conformational changes in NPC1L1 that are necessary for cholesterol flux across the membrane. This model is consistent with the human genetic NPC1L1 polymorphisms and with preclinical data that indicate inhibitor absorption is not critical for in vivo efficacy of the drugs.
( (Fig. 1A) Immunoprecipitation was monitored at the protein level by immunoblotting with an anti-K v 1.1 antibody and silver staining combined with LC-MS/MS sequencing. Immunoblotting analysis revealed that two bands, present in the immunoprecipitated material with apparent molecular weights of 125 and 165 kDa, are identical to those detected in solubilized and unbound material ( (Fig. 2 A Inset and  B) . However, at radioligand concentrations (50-150 nM), where a reliable specific binding component can be measured, it is possible to characterize the pharmacological properties of the binding reaction. Under these conditions, the ability of ␤-lactams to compete with [ 3 H]AS is consistent with binding of the radioligand to Because of the significant difference in [
3 H]AS-binding affinity between dog and mouse NPC1L1, a series of full-length dog/mouse NPC1L1 chimeras possessing progressively larger domains of dog NPC1L1 were generated and characterized to determine the region of NPC1L1 responsible for high-affinity ligand binding (Fig. 3A , Table S2 ). Results from these experiments are illustrated in Fig. 3B . (Fig. 3D ), K d s of 1.04 Ϯ 0.37 nM (n ϭ 13) and 79.9 Ϯ 46.4 nM (n ϭ 3) for dog NPC1L1 and chimera 8, respectively]. These data, taken together, suggest that the major molecular determinants of high-affinity [ 3 H]AS binding are present in loop C of dog NPC1L1.
To determine whether loop C alone is capable of binding [ 3 H]AS, we attempted to express amino acids 374-634 of dog NPC1L1 in bacteria as a DsbC or GST fusion protein or in mammalian cells as a CD8-loop C or maxiK ␤-loop C fusion protein (data not shown). However, specific [ 3 H]AS binding could not be detected with any of these constructs after transient transfection in TsA201 cells. Although our arbitrary choice of fusion protein junctions near the predicted TMD2 and 3 helix:loop interfaces may have affected the correct folding and/or stability of the loop C fusion proteins, it is also possible that loop C requires interaction(s) with other region/ domain(s) of NPC1L1 for correct folding, stability and/or [ 3 H]AS binding.
Loop C is predicted to be Ͼ250 aa in length, and therefore, in an effort to narrow the molecular determinants of high-affinity [ 3 (Fig. 3E) . Results from these experiments clearly indicate that the region of loop C containing amino acids 510-571 is critical for high-affinity [ 3 H]AS binding [ (Fig. 3E ), K d s of 56.9 Ϯ 0.9 nM (n ϭ 2), 51.45 Ϯ 19.2 (n ϭ 2), and 1.59 Ϯ 0.13 nM (n ϭ 4), respectively].
Gain and Loss of High-Affinity [ 3 H]AS-Binding Mutations in NPC1L1.
Alignment of several NPC1L1 species with different [ 3 H]ASbinding affinities across the 510-to 571-aa region identifies nine positions of sequence variation (Fig. 4A) . Although dog, rat, and human NPC1L1 bind [
3 H]AS with affinities of Ϸ1, 5, and 10 nM, respectively, mouse NPC1L1 binds [ 3 H]AS with significantly lower affinity. Therefore, we searched for amino acid positions identical in dog, rat, and human NPC1L1 and different in mouse NPC1L1, reasoning that these substitutions may be responsible for the changes in [ 3 H]AS-binding affinity. This led to the identification of two positions, amino acids 532 and 543, as candidates for highaffinity [ 3 H]AS binding in dog NPC1L1. Therefore, these two dog residues were then replaced individually or together into the full-length mouse NPC1L1. Individual substitutions at either position significantly increased [ 3 H]AS-binding affinity to mouse NPC1L1 [ (Fig. 4B) , K d s of 1.04 Ϯ 0.37 nM (n ϭ 13), 13.25 Ϯ 3.22 nM (n ϭ 4), and 9.3 Ϯ 1.86 nM (n ϭ 4) for dog NPC1L1, Tyr-5323Phe and Ile-5433Met, respectively]. Furthermore, in the double mouse mutant Tyr-5323Phe/Ile-5433Met, [ 3 H]ASbinding affinity is only 3-fold lower than that of dog NPC1L1 [( Although there are subtle differences in the extent of change in [ 3 H]AS binding between reciprocal dog3mouse and mouse3dog NPC1L1 chimeras/mutations, these variations are relatively minor in energetic terms. However, given that substituting residues and/or regions of dog NPC1L1 loop C into mouse NPC1L1 (e.g., chimeras 2, 7, 11, and the double mouse mutant Tyr-5323Phe/Ile5433Met) did not result in high-affinity [ 3 H]AS binding indistinguishable from wild-type dog NPC1L1, we cannot completely exclude the possibility that other regions of NPC1L1 may also contribute to [ 3 H]AS binding.
Discussion
The current study used biochemical and proteomic approaches to determine the nature of the interaction between NPC1L1 and EZE analogs. The results showing that the noncovalent [ 3 H]AS-NPC1L1 complex can be affinity purified from MDCKII cells, a pharmacologically validated system for EZE-sensitive cholesterol flux (8), provide compelling evidence that EZE analogs bind to NPC1L1 directly.
Immunoblot analysis showed good quantitative correlation of NPC1L1 with [ 3 H]AS binding during NPC1L1 affinity purification. In line with the specific band pattern obtained from silver staining of the affinity-purified material, comprehensive high-sensitivity nano-LC-MS/MS sequencing identified dog NPC1L1 as the dominant specifically purified protein. In addition, Trx-related protein, a homolog of ER protein disulphide isomerases, has been identified as a putative low-abundance interaction partner. Although the physiological relevance of this protein is unclear, it may provide an efficient means of folding the Cys-rich luminal loops of NPC1L1. Notably, our findings provided no evidence that support physical interaction between NPC1L1 and SR-B1, CD36, CD13, caveolin-1/annexin-2 (9), or the existence of other yet-unknown NPC1L1 interaction partners in MDCKII cells.
Alignment of NPC1L1 with mammalian and prokaryotic homologues, for which structural information is available, indicates that NPC1L1 is likely to consist of 13 TMD with an extracellular N terminus and cytoplasmic C terminus (21) . Based on our demonstration that dog NPC1L1 binds [ 3 H]AS directly, we exploited the differences in affinity between dog and mouse NPC1L1 for EZE analogs in a chimeric approach to identify a region of extracellular loop C between positions 510 and 571 that is critical for high-affinity [ 3 H]AS binding (Fig. 5) . In particular, two amino acids present in this region of dog NPC1L1 (Phe-532 and Met-543) and conserved in human NPC1L1 appear to represent key molecular determinants for the high-affinity interaction of [ 3 H]AS and EZE analogs. Physiologically, an extracellular binding site for transmembrane domains (CAIs) would explain the efficacy of a minimally absorbed CAI from microbia (Ͻ0.4% bioavailability) (22, 23) that is currently being developed for the treatment of hypercholesterolemia. Although the compound possesses minimal absorption, it has comparable preclinical efficacy to EZE, which is absorbed into the systemic circulation (22) . These observations are consistent with the notion that CAIs bind to extracellular region(s) of NPC1L1 in the intestinal lumen and block the ability of NPC1L1 to transport cholesterol into the enterocyte cytoplasm. In addition, these data do not support the notion from other studies that inhibition of NPC1L1 by these agents occurs from the cytoplasm of the enterocyte (24) .
Until recently, the only direct information on the regions and residues of NPC1L1 implicated in cholesterol absorption was implied from human genetics (17) . Sequencing of NPC1L1 coding regions in individuals from the Dallas Heart Study who had the highest and lowest cholesterol absorption, determined by ratio of campesterol to lathosterol (Ca:L), identified rare nonsynonymous variants in human NPC1L1 associated with hypoabsorption of cholesterol (17) . Although most of the hypoabsorption polymorphisms are distributed evenly throughout the primary sequence of human NPC1L1, a single hotspot exists in loop C, close to the two residues that we have shown to be critical for [ 3 H]AS binding (Fig.  5 ). These observations are compatible with the notion that individual changes in the conformation of loop C at distinct and independent sites (polymorphisms and [ 3 H]AS-binding determinants) translate into an effect on cholesterol transport without these sites communicating with each other. However, heterologous expression of human NPC1L1 loop C hypoabsorption polymorphisms in CHO-K1 cells have recently been associated with low levels of protein expression (25) , and our preliminary data indicate that the affinity of [ 3 H]AS for these loop C hypoabsorption polymorphisms is not significantly altered, whereas site density appears to be reduced (data not shown), providing an alternative explanation for the hypoabsorption phenotype of these polymorphisms. Although the functional consequences of the loop C polymorphisms and [ 3 H]AS-binding mutations require further elucidation, these data clearly illustrate the importance of loop C in the overall mechanism of cholesterol absorption.
Interestingly, a recent study on NPC1, the closest homologue of NPC1L1 in the SSD-containing proteins, demonstrates that cholesterol binds to its N-terminal domain (19, 20) . Briefly, [ 3 H]Ch binds with the same affinity to full-length human NPC1 and to an N-terminal 240-aa region. Although the physiological significance of cholesterol binding to NPC1 function is unclear (19, 20) , these unexpected observations challenge the dogma that cholesterol would bind only to the SSD of SSD-containing proteins (26) . Although direct binding of cholesterol to the full-length and N-terminal domain of NPC1L1 will be necessary to evaluate their contributions to cholesterol binding and/or function, the results with NPC1 allow us to hypothesize that the N terminus, and not loop C, of NPC1L1 may be involved in cholesterol binding.
Thus, combining the cholesterol-binding data on human NPC1 (19, 20) with our biochemical and proteomic EZE analog binding, human genetics (17) , and preclinical pharmacology (22), we propose a model for NPC1L1-mediated cholesterol flux. In this model, cholesterol binds to the N-terminal region of NPC1L1 and is transported across the membrane through an undisclosed mechanism. Many nonsynonymous polymorphisms in loop C or binding of EZE analogs to a distinct site in loop C would interfere with the conformation of the protein and prevent cholesterol transport. Although the model implies that NPC1L1 functions as a classical transporter, such a mechanism is equally compatible with a receptor-mediated process, and the actual process remains to be elucidated.
Experimental Procedures
Stable MDCKII-Flp cell lines expressing dog NPC1L1 or dog NPC1L1-Kv1.1 were generated as described (8) . Cell-based [ 3 H]AS binding or [ 3 H]cholesterol flux was performed as described (8) . Membranes were prepared by sucrose gradient and solubilization, immunoprecipitation, immunoblot, silver-stained gel, and mass spectral characterization were performed as described in SI Text. Generation of dog/mouse NPC1L1 chimeras and point mutations was performed as described in SI Text. Further experimental details can be found in SI Text.
